Journals / Turkish Journal of Medical Sciences / 2012 / Cilt: 42 - Sayı: 2

Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growth factor expression in non-small cell lung cancer

Pages
281–288
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This indicates that the metastasis biology of lung cancer is a complex and multistep pathogenetic mechanism, although a small number of patients were included in our study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To investigate the role of matrix metalloproteinases (MMPs), MMP-9 and MMP-2, and vascular endothelial growth factor (VEGF) in metastasis and their relationship with survival.
📊
Key Findings & Data:Materials and methods: Using immunohistochemistry analysis, we evaluated MMP-9, MMP-2, and VEGF expressions in paraffin specimens from 91 patients with histopathologically confirmed non-small cell lung cancer and the relationship between MMP-9, MMP-2, and VEGF expressions and the prognosis.
💡
Conclusion & Impact:This indicates that the metastasis biology of lung cancer is a complex and multistep pathogenetic mechanism, although a small number of patients were included in our study.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Key words: Lung cancer · metastasis · matrix metalloproteinases

Abstract

To investigate the role of matrix metalloproteinases (MMPs), MMP-9 and MMP-2, and vascular endothelial growth factor (VEGF) in metastasis and their relationship with survival. Early metastasis is the most common cause of lung cancer death. Angiogenesis and basement membrane damage are necessary for growth and invasion of the tumoral cells. VEGF, involved in angiogenic activity, and MMPs, involved in matrix destruction, are important for metastasis in lung cancer. Materials and methods: Using immunohistochemistry analysis, we evaluated MMP-9, MMP-2, and VEGF expressions in paraffin specimens from 91 patients with histopathologically confirmed non-small cell lung cancer and the relationship between MMP-9, MMP-2, and VEGF expressions and the prognosis. Results: For MMP-9 expression, 52 (57.1%) patients were positive and 39 (42.9%) were negative. Patients whose tumors had MMP-9-positive staining had a shorter duration of survival than patients whose tumors had no expression, but it was not statistically significant (14.1 ± 1.7 (median: 12) vs. 16.7 ± 2.2 (median: 15), P > 0.05). For MMP-2 expression, 13 (14.3%) patients were positive and 78 (85.7%) were negative. Patients whose tumors had MMP-2-positive staining had a shorter duration of survival than patients whose tumors had no expression, but it was not statistically significant (12.6 ± 3.6 (median: 8) vs. 16.1 ± 1.5 (median: 14), P > 0.05). For VEGF expression, 34 (37.4%) patients were positive and 57 (62.6%) were negative. There was no significant relationship between the duration of survival for patients whose tumors had VEGF-positive and VEGF-negative staining (15.3 ± 1.7 (median: 18) vs. 15.6 ± 2.1 (median: 13), P > 0.05). Conclusion: Angiogenesis and basement membrane damage are the main components for metastasis, but there was no significant relationship between MMP and VEGF expressions and prognosis. This indicates that the metastasis biology of lung cancer is a complex and multistep pathogenetic mechanism, although a small number of patients were included in our study.

Özet

To investigate the role of matrix metalloproteinases (MMPs), MMP-9 and MMP-2, and vascular endothelial growth factor (VEGF) in metastasis and their relationship with survival. Early metastasis is the most common cause of lung cancer death. Angiogenesis and basement membrane damage are necessary for growth and invasion of the tumoral cells. VEGF, involved in angiogenic activity, and MMPs, involved in matrix destruction, are important for metastasis in lung cancer. Materials and methods: Using immunohistochemistry analysis, we evaluated MMP-9, MMP-2, and VEGF expressions in paraffin specimens from 91 patients with histopathologically confirmed non-small cell lung cancer and the relationship between MMP-9, MMP-2, and VEGF expressions and the prognosis. Results: For MMP-9 expression, 52 (57.1%) patients were positive and 39 (42.9%) were negative. Patients whose tumors had MMP-9-positive staining had a shorter duration of survival than patients whose tumors had no expression, but it was not statistically significant (14.1 ± 1.7 (median: 12) vs. 16.7 ± 2.2 (median: 15), P > 0.05). For MMP-2 expression, 13 (14.3%) patients were positive and 78 (85.7%) were negative. Patients whose tumors had MMP-2-positive staining had a shorter duration of survival than patients whose tumors had no expression, but it was not statistically significant (12.6 ± 3.6 (median: 8) vs. 16.1 ± 1.5 (median: 14), P > 0.05). For VEGF expression, 34 (37.4%) patients were positive and 57 (62.6%) were negative. There was no significant relationship between the duration of survival for patients whose tumors had VEGF-positive and VEGF-negative staining (15.3 ± 1.7 (median: 18) vs. 15.6 ± 2.1 (median: 13), P > 0.05). Conclusion: Angiogenesis and basement membrane damage are the main components for metastasis, but there was no significant relationship between MMP and VEGF expressions and prognosis. This indicates that the metastasis biology of lung cancer is a complex and multistep pathogenetic mechanism, although a small number of patients were included in our study.

🔖

Cite This Article

MEMİŞ, L., AKYÜREK, N., KARAKAYA, J., YILMAZ, Ş., YURDAKUL, A., ÖZTÜRK, C. (2022). Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growth factor expression in non-small cell lung cancer. Turkish Journal of Medical Sciences, Cilt: 42 - Sayı: 2, 281–288. https://ajindex.com/articles/611262

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Sawicki G, Matsuzaki A, Jankowska-Wieczorek A. Expression of the active form of MMP-2 on the surface of leukemic cells accounts for their in vitro invasion. J Cancer Res Clin Oncol 1998; 124: 245-52.
  2. Ohta Y, Watanabe Y. Current concepts of angiogenesis related to primary lung cancer. In: Lung cancer. Pass IH, editor. 2nd ed. Philadelphia (PA): Lippincott Williams-Wilkins; 2000. p.199-210.
  3. Robbins SL, Kumar V. Neoplasia. In: Cotran RS, Vinay K, Collins T, Robbins SL, editors. Robbins & Cotran Pathologic basis of disease. 6th ed. Philadelphia (PA): W.B. Saunders Company; 1999. p.301-2.
  4. Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T et al. Infl uence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small cell lung cancer. Br J Cancer 2001; 85: 1706-12. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6. Junker K. Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer 2001; 33: 17-24.
  5. Poon RTP, Fan TS, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.
  6. Aikawa H, Takahashi H, Fujimura S, Sato M, Endo C, Sakurada A et al. Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer. Anticancer Res 1999; 19: 4305-10.
  7. Ohta Y, Tomita Y, Oda M, Watanabe S, Murakami S, Watanabe Y et al. Tumor angiogenesis and recurrence in stage I non- small cell lung cancer. Ann Th orac Surg 1999; 68: 1034-8.
  8. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer 2001; 33: 125-32.
  9. Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B et al. Quantitative analysis of basic fi broblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998; 78: 765-70.
  10. Volm M, Koomagi R, Mattern J. PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 1999; 19: 651-6.
  11. Volm M, Mattern J, Koomagi R. Angiostatin expression in non-small cell lung cancer. Clin Cancer Res 2000; 6: 3236-40.
  12. Lamoreaux WJ, Fitzgerald MEC, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998; 55: 29-42. Co